Senior Manager, Technical Accounting and SEC Reporting

Who We Are:

Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.

The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.

Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.

The Role:

We are seeking an experienced accounting professional to lead SEC reporting and technical accounting functions. This role oversees the preparation and review of SEC filings (10-Q, 10-K, Proxy, 8-K), ensures compliance with US GAAP and Sarbanes-Oxley, and manages internal controls documentation.

Responsibilities:

• Oversee preparation of SEC reporting documents (10-Q, 10-K, Proxy, 8K) with Senior Accountant

• Prepare and/or review footnote support schedules, tie-out binders for SEC filings and disclosure checklists

• Review XBRL tagging

• Collaborate with other members of accounting to obtain data for SEC financial preparation

• Prepare and review journal entries and account reconciliations as part of the monthly and quarterly close process based on assigned accounting areas

• Assist with research and preparation of technical accounting position papers

• Review of newly issued accounting and documentation of potential impact

• Work closely with the accounting team, internal and external auditors to support the quarterly review and annual audit process

• Collaborate with VP, Controller and Legal on Form 4s and other ad-hoc filings

• Oversee the monthly internal controls documentation process and document assessment of operating effectiveness and evaluation of any deficiencies identified

• Oversee the accounting for stock compensation expense

• Work with accounting team on quarterly and annual tax provision and other tax projects

• Assist on special projects as needed

Qualifications:

• Bachelor’s Degree or equivalent in Accounting or Business

• CPA preferred

• 6+ years of Big 4 public accounting experience

• 1-3 years finance and accounting experience in publicly held companies preferred

• Experience with filing management system required, Active Disclosure preferred

• Strong knowledge of US GAAP and SEC reporting requirements

• Proficiency in accounting software, NetSuite strongly preferred and Agiloft and/or Jaggaer e-procurement experience a plus

• Excellent organizational skills and attention to detail

• Excellent analytical, organizational, and communication skills

• Ability to manage multiple tasks and priorities in a fast-paced environment

• Sarbanes-Oxley experience required

• Pharma/biotech experience strongly preferred

• Ability to be on-site in Waltham, MA required; will require some travel to Boulder, CO location

Salary Range:

$150,000 - 175,000 USD

Target Bonus: 15%

Exact compensation will vary based on skills, experience, and location.

Our Locations

Waltham, MA: Our Boston office includes an open office layout that has recently undergone a makeover designed for collaboration and giving our employees the best work place possible. Free access is provided for both on-site parking and gym facilities in the building.

Boulder, CO: We have just moved into our new state-of-the art Research Facility in the fast-growing biopharmaceutical hub in the greater Denver/Boulder corridor. Our CEO is based full-time in this location and we are proud to call this the home of Cogent’s discovery research organization.

Our Offer To You

To attract the very best talent, we offer a generous benefits package that includes competitive pay, performance-based bonus, stock options, insurance coverage (health, dental, life, and disability), competitive time-off, a 401(k) plan, and commuter/parking benefits.

We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need.